Vaxart Files Proxy Materials, Formerly Aviragen

TL;DR

Vaxart (VXRT) filed proxy docs, no fee. Formerly Aviragen.

AI Summary

Vaxart, Inc. filed a Definitive Additional Materials (DEFA14A) on August 8, 2025. This filing relates to the company's proxy statement and indicates no fee was required for this filing. Vaxart, Inc. was formerly known as Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., and NABI BIOPHARMACEUTICALS.

Why It Matters

This filing is a routine proxy statement update, providing shareholders with information related to corporate governance and voting matters. It also details the company's historical name changes.

Risk Assessment

Risk Level: low — This filing is a standard proxy statement update and does not contain new financial information or significant corporate actions that would inherently increase risk.

Key Numbers

• 0001437749-25-025769 — Accession Number (Unique identifier for the filing)

Key Players & Entities

• Vaxart, Inc. (company) — Registrant
• Aviragen Therapeutics, Inc. (company) — Former company name
• Biota Pharmaceuticals, Inc. (company) — Former company name
• NABI BIOPHARMACEUTICALS (company) — Former company name
• 20250808 (date) — Filing date

FAQ

Key Financial Figures

• $1 — TC-listed stocks or those trading below $1. Likewise, some brokerage platforms lim

Filing Documents

• vxrt20250808_defa14a.htm (DEFA14A) — 34KB
• 0001437749-25-025769.txt ( ) — 36KB

From the Filing

vxrt20250808_defa14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to 240.14a-12 VAXART, INC. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box) No fee required. Fee paid previously with preliminary materials Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. Vaxart CEO Issues Letter to Stockholders - Management Urges Stockholders to Vote FOR Reverse Stock Split Proposal by 11:59 p.m. Eastern Time on September 4, 2025 - SOUTH SAN FRANCISCO, Calif., August 8, 2025 — Vaxart, Inc. (OTCQX: VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today issued the following letter to its stockholders from its President & Chief Executive Officer, Steven Lo. Dear Vaxart, Inc. Stockholders: We deeply appreciate your continued support and commitment to Vaxart's mission. Many of you have stood by us through both exciting breakthroughs and challenging moments, and we want to acknowledge that journey as we provide an important update on our efforts to relist Vaxart's common stock on Nasdaq. Why Relisting Matters We understand that some stockholders—particularly those who have been with us for years—may feel frustrated by the current share price and are skeptical about another reverse stock split proposal. We hear you and we share that frustration. We have worked hard to advance our science and will continue to make every effort to create value for our stockholders. But we also want to be transparent about why regaining our Nasdaq listing is a strategic imperative for Vaxart's future and will ultimately maximize long-term value for all stockholders. Being listed on Nasdaq offers critical advantages that directly impact our ability to continue to advance toward developing and commercializing our products, making Vaxart and our vaccines more valuable to potential non-dilutive, strategic and other investors and ultimately giving us the best chance to see share price appreciation. Nasdaq listing provides: Broader Access to Investors : Many institutional investors and life sciences funds are restricted from investing in OTC-listed stocks or those trading below $1. Likewise, some brokerage platforms limit access to OTC-listed stocks for retail investors. A Nasdaq listing expands the pool of potential investors—retail and institutional alike. Greater Visibility and Analyst Coverage : Most sell-side analysts do not cover OTC-listed stocks. Relisting would increase the likelihood of analyst coverage, which can enhance market visibility and help all investors make more informed decisions. Enhanced Financial Flexibility : Drug development is capital intensive. While we are grateful for BARDA's support, recent events such as the Stop Work Order the Company has received demonstrate that we must rely on multiple sources for funding, allowing us to be prepared for regulatory shifts or opportunities to accelerate promising programs. A Nasdaq listing improves our ability to secure financing on more favorable terms—helping to protect long-term value and reduce dilution risk. Improved Market Perception : Nasdaq is home to many of the world's most respected biotech companies. Relisting would reaffirm our position as a serious innovator in vaccine science and offer greater transparency, liquidity, and stability for all investors. Stronger Partnership Positioning : A Nasdaq listing provides credibility and leverage in negotiations, which enhances our position as we explore collaborations to accelerate our pipeline. Additionally, we believe the enhanced liquidity and rigorous rules of Nasdaq help protect stockholder interests and could weigh favorably on stock price. Reverse Stock Split Proposal We recognize that reverse stock splits are often met with concern, especially among retail investors. Let us be clear: we do not take this decision lightly. We share in the disappointment that the share price has remained below the Nasdaq minimum bid price even when no reverse split proposal was effected. Given our current valuation and absent substantial near-term appreciation, a reverse stock split remains the most viable path to relist on Nasdaq. We have appealed Nasdaq's suspension and are scheduled to meet with their hearings panel on August 14, 2025. But based on our discussions and the realities of the

View Full Filing

View this DEFA14A filing on SEC EDGAR